https://academic.oup.com/biostatistics/article/20/2/273/4817524?login=false
DXB sitting here with multiple Phase 3 studies fully funded at under $100M market cap ... I like these odds.
This is what we are here for, taking a roll at the dice and we are lucky enough to roll it 3 times this year!
2022 is the year the full potential of DXB will be made visible. The risk/reward ratio on offer is very attractive.
I like the odds.
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $253.1M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 45.5¢ | $1.771M | 3.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34765 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 26998 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |